Jubilant Pharmova Ltd

Jubilant Pharmova reported Q1 FY27 results with revenue increasing 17% year-on-year to ₹2,229 Cr, driven by strong growth across all business segments, particularly CDMO Sterile Injectables. However, EBITDA saw an 11% decline to ₹268 Cr and PAT fell 45% to ₹56 Cr, mainly due to the unavailability of high-margin SPECT radiopharmaceutical products and increased operating expenses. The company expects EBITDA margins to improve from H2 FY27 as SPECT products become available. Key segments like Radiopharma and Radiopharmacy showed revenue growth, with significant investments planned for PET manufacturing network expansion. Progress was also noted in Allergy Immunotherapy, CDMO, Generics, and Proprietary Novel drugs businesses.

Consolidated revenue rose 17.3% YoY to ₹2,229.4 Cr, in line with (slightly ahead of) the ₹2,100-2,200 Cr range flagged in our pre-result preview and matching management's own "solid growth of 17% on YoY basis" framing. But consolidated PAT fell 45.0% YoY and 52.7% QoQ to ₹56.4 Cr, well short of the ₹70-90 Cr PAT range the preview had set as the bar. Since neither this quarter nor the year-ago quarter carried exceptional items (Q4 FY26, by contrast, had a ₹13.7 Cr exceptional item), the decline is a clean operational one, not a one-off swing. EPS came in at ₹3.57 versus ₹6.49 a year ago and ₹7.55 last quarter. EBITDA, per management, was ₹268 Cr for the quarter — an implied margin of ~12.0%, down from ~15.2% a year ago and ~14.2% last quarter, missing the preview's 15-16% expectation. Management attributes this to the unavailability of high-margin SPECT radiopharmaceutical products, which shows up directly in the segment data: Radiopharma segment profit fell to ₹78.0 Cr from ₹98.6 Cr YoY even though segment revenue grew to ₹1,022.1 Cr from ₹868.6 Cr. The sharper margin hit sits in CDMO Sterile Injectables, exactly the segment management called out as a growth driver: revenue there jumped 32.4% YoY to ₹519.8 Cr on technology-transfer income from the new/third line, but segment profit collapsed to ₹7.3 Cr from ₹43.1 Cr — the new capacity is adding revenue but diluting margins, the Montreal-related capacity question the Street was watching into this print. Jubilant Pharmova gives no formal quarterly guidance on record, so this print is judged against Street's implicit bar rather than a company target — on that basis it is a revenue beat but a clear profit and margin miss. The tax-rectification tailwind flagged as a pre-result watch item did not materialise this quarter: the effective tax rate held near 34.7% (₹30.0 Cr tax on ₹86.4 Cr PBT), close to last year's 33.6%. On the corporate calendar, the board meeting was pushed from Aug 5 to Aug 10 to finalise these results, and the company has an AGM scheduled for Aug 26 alongside the FY26 dividend payout — neither bears on this quarter's operating numbers. Standalone, a much smaller slice of the group, posted PAT of ₹7.3 Cr on revenue of ₹67.1 Cr, EPS ₹0.46.

Jubilant Pharmova Ltd announced that its Board of Directors met on August 10, 2026, to approve the unaudited financial results for the quarter ended June 30, 2026. The results, both standalone and consolidated, along with the limited review report, have been submitted. These documents will also be available on the company's official website. The meeting concluded after reviewing these financial statements.

Jubilant Pharmova Ltd has informed BSE that its Board of Directors meeting, originally scheduled for August 7, 2026, has been postponed due to unavoidable circumstances. The meeting will now be held on August 10, 2026. The primary agenda remains the consideration and approval of the Un-audited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. The trading window for company securities will remain closed until August 12, 2026, for designated persons and their immediate relatives.

Jubilant Pharmova Ltd has informed shareholders about the deduction of tax at source (TDS) on the proposed Final Dividend for FY 2025-26. The dividend of ₹5 per equity share is subject to shareholder approval at the upcoming AGM. The record date for eligibility is July 24, 2026. The company will withhold taxes as per the Income-tax Act, 2025. For resident individual shareholders, TDS is not applicable if the total dividend does not exceed ₹10,000. Higher rates (10% or 20%) apply based on PAN status and linkage. Shareholders are urged to update their PAN details by August 14, 2026, to ensure correct TDS application or avail lower/nil deduction certificates.

Jubilant Pharmova Ltd has dispatched letters to shareholders whose email IDs are not registered, providing weblinks to access the Annual Report for FY 2025-26, the Notice of the 48th Annual General Meeting (AGM), and TDS Communication. The AGM is scheduled for August 26, 2026, via Video Conferencing. Shareholders are urged to register or update their email addresses to receive future communications electronically. Contact details for the company's Registrar and Share Transfer Agent are provided for assistance.

Jubilant Pharmova Ltd has announced its 48th Annual General Meeting (AGM) to be held on Wednesday, August 26, 2026, at 11:00 a.m. IST via Video Conferencing. The company has also released its Annual Report for the Financial Year 2025-26 and the AGM Notice, which includes e-voting instructions. Key agenda items include the adoption of audited standalone and consolidated financial statements for FY2025-26, declaration of a dividend of ₹5 per equity share, and the re-appointment of directors Mr. Hari S. Bhartia and Mr. Arjun Shanker Bhartia who are retiring by rotation. The cut-off date for voting rights is August 19, 2026, with remote e-voting commencing on August 23, 2026.

Jubilant Pharmova Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, as required by Regulation 34 of the Listing Regulations. The report, which forms part of the Annual Report, provides comprehensive disclosures on the company's environmental, social, and governance (ESG) performance on a consolidated basis. Key business segments include Radiopharma (44.57% turnover), Contract Development and Manufacturing Organisation - Sterile Injectables (21.19%), and Contract Research, Development and Manufacturing Organisation (14.70%). The company operates 2 national and 3 international plants, serving 21 domestic and 74 international markets, with exports contributing 63.53% to its turnover. The report also details employee and worker demographics, with a total of 3786 employees and 2600 workers.

Jubilant Pharmova Ltd has announced its 48th Annual General Meeting (AGM) to be held on Wednesday, August 26, 2026, at 11:00 a.m. IST via Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The company has dispatched the Annual Report for FY 2025-26 and the AGM Notice to its members. Key agenda items include the adoption of audited standalone and consolidated financial statements for FY 2025-26, declaration of a dividend of ₹5 per equity share, and the re-appointment of directors Mr. Hari S. Bhartia and Mr. Arjun Shanker Bhartia. The cut-off date for determining voting eligibility is August 19, 2026, with remote e-voting commencing on August 23, 2026.

Jubilant Pharmova Ltd has announced the details for its 48th Annual General Meeting (AGM) scheduled for August 26, 2026. The AGM will be held via Video Conferencing (VC) / Other Audio-Visual Means (OAVM) at 11:00 a.m. (IST). Key agenda items include the adoption of the Audited Standalone and Consolidated Financial Statements for FY 2025-26, declaration of a dividend of ₹5 per equity share, and the re-appointment of directors Mr. Hari S. Bhartia and Mr. Arjun Shanker Bhartia. The Annual Report and AGM Notice for FY 2025-26 have been dispatched to shareholders, with e-voting facilities available from August 23 to August 25, 2026. The cut-off date for eligibility to vote is August 19, 2026.